Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir.

Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir.

Item
http://www.wikidata.org/entity/Q38204368
Hepatitis C genotype 4: The past, present, and futureNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewCurrent status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replicationHealth-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in EgyptDevelopment of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon.Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.How much management is necessary? Sustaining the benefit of achieving a sustained virologic response to hepatitis C.Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry.Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
P2860

Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir.

Item
http://www.wikidata.org/entity/Q38204368
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Benefit-risk assessment of new ...... on simeprevir and sofosbuvir.
@en
type
label
Benefit-risk assessment of new ...... on simeprevir and sofosbuvir.
@en
prefLabel
Benefit-risk assessment of new ...... on simeprevir and sofosbuvir.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Benefit-risk assessment of new ...... on simeprevir and sofosbuvir.
@en
P2093
P2860
P304
P31
P356
P407
P478
P577
P5875
P698
P921
P932